Search Results - "Brown, JE"

Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases by Saad, F., Brown, J.E., Van Poznak, C., Ibrahim, T., Stemmer, S.M., Stopeck, A.T., Diel, I.J., Takahashi, S., Shore, N., Henry, D.H., Barrios, C.H., Facon, T., Senecal, F., Fizazi, K., Zhou, L., Daniels, A., Carrière, P., Dansey, R.

“…Osteonecrosis of the jaw (ONJ) has been reported in patients receiving bisphosphonates for metastatic bone disease. ONJ incidence, risk factors, and outcomes…”
Get full text

Salivary duct strictures: nature and incidence in benign salivary obstruction by Ngu, R K, Brown, J E, Whaites, E J, Drage, N A, Ng, S Y, Makdissi, J

“…The aim of this study was to establish the incidence and character of salivary duct strictures by carrying out a 10 year retrospective review. Salivary gland…”
Get full text

Aldehyde Oxidase-catalysed Oxidation of Methotrexate in the Liver of Guinea-pig, Rabbit and Man by JORDAN, C. GERALDINE M., RASHIDI, MOHAMMED R., LALJEE, HUSSAIN, CLARKE, STEPHEN E., BROWN, JOHN E., BEEDHAM, CHRISTINE

“…Although 7‐hydroxymethotrexate is a major metabolite of methotrexate during high‐dose therapy, negligible methotrexate‐oxidizing activity has been found…”
Get full text

Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics by Lipton, A, Fizazi, K, Stopeck, A.T, Henry, D.H, Smith, M.R, Shore, N, Martin, M, Vadhan-Raj, S, Brown, J.E, Richardson, G.E, Saad, F, Yardley, D.A, Zhou, K, Balakumaran, A, Braun, A

“…Abstract Background Analyses of phase III trials showed that denosumab was superior to zoledronic acid (ZA) in preventing skeletal-related events (SREs)…”
Get full text

Management of cancer treatment-induced bone loss by Coleman, Robert E., Rathbone, Emma, Brown, Janet E.

“…Cancer treatments can have severe adverse effects on bone health, and can thus increase the risk of fragility fractures both during therapy and in later life…”
Get full text

Denosumab in patients with cancer—a surgical strike against the osteoclast by Brown, Janet E., Coleman, Robert E.

“…Recent phase III trials of denosumab, a monoclonal antibody that inhibits RANKL, have demonstrated superiority over zoledronic acid in reducing skeletal…”
Get full text

The ERICA Tool by Brown, J.E., Alfonso, B., Avila, R., Beresford, N.A., Copplestone, D., Pröhl, G., Ulanovsky, A.

“…The ERICA Tool is a computerised, flexible software system that has a structure based upon the ERICA Integrated Approach to assessing the radiological risk to…”
Get full text

Efficacy and challenges of a culturally relevant intervention to improve attitudes to aging by Seah, Siang Joo, Brown, Laura JE, Bryant, Christina

“…Objectives: Attitudes to aging have been linked with important health outcomes. It is unclear whether interventions to improve attitudes to aging are effective…”
Get full text

Identification and validation of DOCK4 as a potential biomarker for risk of bone metastasis development in patients with early breast cancer by Westbrook, Jules A, Wood, Steven L, Cairns, David A, McMahon, Kathryn, Gahlaut, Renu, Thygesen, Helene, Shires, Mike, Roberts, Stephanie, Marshall, Helen, Oliva, Maria R, Dunning, Mark J, Hanby, Andrew M, Selby, Peter J, Speirs, Valerie, Mavria, Georgia, Coleman, Robert E, Brown, Janet E

“…Skeletal metastasis occurs in around 75% of advanced breast cancers, with the disease incurable once cancer cells disseminate to bone, but there remains an…”
Get full text

Synthesis, analysis and biological evaluation of novel indolquinonecryptolepine analogues as potential anti-tumour agents by Le Gresley, A, Gudivaka, V, Carrington, S, Sinclair, A, Brown, J E

“…A small library of cryptolepine analogues were synthesised incorporating halogens and/or nitrogen containing side chains to optimise their interaction with the…”
Get more information

Predictive Value of Bone Resorption and Formation Markers in Cancer Patients With Bone Metastases Receiving the Bisphosphonate Zoledronic Acid by COLEMAN, Robert E, MAJOR, Pierre, COOK, Richard, LIPTON, Allan, BROWN, Janet E, LEE, Ker-Ai, SMITH, Matthew, SAAD, Fred, MING ZHENG, YONG JIANG HEI, SEAMAN, John

“…Three large, randomized trials of patients with bone metastases recently demonstrated that zoledronic acid reduces the risk of skeletal-related events. These…”
Get full text

An international database of radionuclide concentration ratios for wildlife: development and uses by Copplestone, D., Beresford, N.A., Brown, J.E., Yankovich, T.

“…A key element of most systems for assessing the impact of radionuclides on the environment is a means to estimate the transfer of radionuclides to organisms…”
Get full text

Making simple changes to the way a starchy carbohydrate meal is prepared can significantly reduce the postprandial glucose response by Robertson, T.M., Brown, J.E., Robertson, M.D.

Get full text

Bone Turnover Markers as Predictors of Skeletal Complications in Prostate Cancer, Lung Cancer, and Other Solid Tumors by Brown, Janet E., Cook, Richard J., Major, Pierre, Lipton, Allan, Saad, Fred, Smith, Matthew, Lee, Ker-Ai, Zheng, Ming, Hei, Yong-Jiang, Coleman, Robert E.

“…Background: Whether bone markers have prognostic value in patients with bone metastases is unknown. We investigated this question in patients with bone…”
Get full text

Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04) by Coleman, R.E., Collinson, M., Gregory, W., Marshall, H., Bell, R., Dodwell, D., Keane, M., Gil, M., Barrett-Lee, P., Ritchie, D., Bowman, A., Liversedge, V., De Boer, R.H., Passos-Coelho, J.L., O'Reilly, S., Bertelli, G., Joffe, J., Brown, J.E., Wilson, C., Tercero, J.C., Jean-Mairet, J., Gomis, R., Cameron, D.

“…Adjuvant bisphosphonates improve disease outcomes in postmenopausal early breast cancer (EBC) but the long-term effects are poorly described. The AZURE trial…”
Get full text

Evolving Role of Bone Biomarkers in Castration-Resistant Prostate Cancer by Brown, Janet E., Sim, Sheryl

“…The preferential metastasis of prostate cancer cells to bone disrupts the process of bone remodeling and results in lesions that cause significant pain and…”
Get full text

Abstract P1-05-01: Breast cancer cell-derived IL-1B drives metastasis and colonisation of the bone microenvironment by Ottewell, PD, Lefley, DV, Freeman, K, Gregory, WM, Hanby, AM, Spicer-Hadlington, AR, Liu, X, Bradbury, SM, Hambley, L, Allocca, G, Cookson, V, Kruithof de-Julio, M, Coleman, RE, Brown, JE, Holen, I, Tulotta, C

“…Background: Breast cancer bone metastases are incurable and new therapeutic targets needed. After homing and colonising bone, cancer cells remain dormant,…”
Get full text

The IAEA handbook on radionuclide transfer to wildlife by Howard, B.J., Beresford, N.A., Copplestone, D., Telleria, D., Proehl, G., Fesenko, S., Jeffree, R.A., Yankovich, T.L., Brown, J.E., Higley, K., Johansen, M.P., Mulye, H., Vandenhove, H., Gashchak, S., Wood, M.D., Takata, H., Andersson, P., Dale, P., Ryan, J., Bollhöfer, A., Doering, C., Barnett, C.L., Wells, C.

“…An IAEA handbook presenting transfer parameter values for wildlife has recently been produced. Concentration ratios (CRwo-media) between the whole organism…”
Get full text

Osteonecrosis of the Jaw and Oral Health–Related Quality of Life After Adjuvant Zoledronic Acid: An Adjuvant Zoledronic Acid to Reduce Recurrence Trial Subprotocol (BIG01/04) by RATHBONE, Emma J, BROWN, Janet E, JYOTHIRMAYI, Rema, CHAKRABORTI, Prabir, YUILLE, Frances, COLEMAN, Robert E, MARSHALL, Helen C, COLLINSON, Michelle, LIVERSEDGE, Victoria, MURDEN, Geraldine A, CAMERON, David, BELL, Richard, SPENSLEY, Saiqa, AGRAWAL, Rajiv

“…In patients with early breast cancer, adjuvant zoledronic acid (zoledronate) may reduce recurrence and improve survival. However, zoledronate is associated…”
Get full text

Approaches to providing missing transfer parameter values in the ERICA Tool – How well do they work? by Brown, J.E., Beresford, N.A., Hosseini, A.

“…A required parameter for the ERICA Tool is the concentration ratio (CR), which is used to describe the transfer from environmental media to a range of…”
Get full text